Abstract 4096
Background
CAPRI, a randomized phase III trial comparing: an intervention combining Nurse Navigators (NNs) and a mobile application vs. Standard of care in cancer patients treated with oral anticancer agents was initiated in 2016 at Gustave Roussy (Villejuif, France). NNs provide regular telephone follow-ups to manage patients’ symptoms and assess toxicities, adherence to treatment and supportive care needs. Patients have access to a mobile application to record tracking data, contact NNs via secure messaging, view therapy and side effect information or store documents. Patient can contact the NNs on a dedicated phone line or by email/secure messaging
Methods
The present analysis involves 3 main data sources: - A questionnaire sent to patients after using for 5 months the CAPRI intervention in order to assess their experience, - Interviews conducted with patients to obtain their feedback of the intervention, - Data extraction from the application and NNs’ interventions over a 24-month period.
Results
Overall, 166 patients (83%) filled the questionnaire. Fifteen interviews were conducted. Patients’ experience with CAPRI intervention is summarized in the table below.Table: CN12
Items | % of patients strongly agree or agree |
---|---|
CAPRI intervention is useful | 96 |
Communicating with the NNs is a reassuring experience | 98 |
CAPRI intervention helps me to better manage my treatment | 79 |
CAPRI intervention is helpful in managing the side effects of my treatment | 87 |
CAPRI intervention helps me to become involved in my treatment | 81 |
CAPRI intervention responds to my expectations and needs for care | 90 |
I am satisfied with the responses from the NNs | 91 |
CAPRI intervention is overly constraining | 9 |
The open-ended comments on the questionnaires and interviews with patients highlighted the importance of listening, having a contact person who is easily reachable, available and empathetic. Concerning the use of the mobile application, 53% of patients reported having tried to connect and only 38% reported monitoring data at least once. By focusing on patient-NNs communication during the study period (817 requests), most contacts are performed by phone (78%) or e-mail (18%) but very few by secure messaging (4%).
Conclusions
Patients’ experience about the intervention was strongly positive. However, the mobile application is poorly used, suggesting that from the patients’ perspective, the presence of NNs is the key of the intervention.
Clinical trial identification
2016-A00254-47.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Fondation Philanthropia - Lombard Odier, Agence Nationale de la Recherche IHU-MMO, ARS Ile de France, Novartis, AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3523 - Results of a global external quality assessment scheme for EGFR testing on liquid biopsy
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3295 - Clinical impact of plasma Next-Generation Sequencing (NGS) in advanced Non-small cell lung cancer (aNSCLC)
Presenter: Laura Bonanno
Session: Poster Display session 3
Resources:
Abstract
5632 - Feasibility study of a ctEGFR prototype assay on the fully automated Idylla™ platform
Presenter: Martin Reijans
Session: Poster Display session 3
Resources:
Abstract
3614 - Enhanced Access to EGFR Molecular Testing in NSCLC using a Cell-Free DNA Tube for Liquid Biopsy
Presenter: Theresa May
Session: Poster Display session 3
Resources:
Abstract
5664 - Analysis of circulating tumor DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients
Presenter: Christina Grech
Session: Poster Display session 3
Resources:
Abstract
4945 - Liquid biopsy and Array Comparative Genomic Hybridization (aCGH)
Presenter: Panagiotis Apostolou
Session: Poster Display session 3
Resources:
Abstract
5746 - Next-generation sequencing panel verification to detect low frequency single nucleotide and copy number variants from mixing cell line studies
Presenter: Rocio Rosas-Alonso
Session: Poster Display session 3
Resources:
Abstract
5901 - Automated rarefaction analysis for precision B and T cell receptor repertoire profiling from peripheral blood and FFPE-preserved tumor
Presenter: Luca Quagliata
Session: Poster Display session 3
Resources:
Abstract
2027 - A Heptamethine cyanine dye is a potential diagnostic marker for Myeloid-Derived Suppressor Cells
Presenter: Chaeyong Jung
Session: Poster Display session 3
Resources:
Abstract
5517 - Molecular fingerprinting in breast cancer (BC) screening using Quantum Optics (QO) technology combined with an artificial intelligence (AI) approach applying the concept of “molecular profiles at n variables (MPnV)”: a prospective pilot study.
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 3
Resources:
Abstract